30 Jul Nvelop Therapeutics
Mansi Shinde, Head of Corporate Development and Strategy
Oct. 7 | 5:30pm | FLW Ballroom G
Cambridge MA
(Private)
Designed to address the limitations of currently available delivery technologies, Nvelop’s modular platforms offer expanded cargo capacity, engineered tissue and cell specificity, enhanced delivery efficiency and safety advantages. Built on two validated in vivo delivery platforms, Nvelop’s customizable particles have the potential for selective and programmable targeting, high In vivo delivery efficiency of a wide range of cargo types and sizes, and full humanization. By enabling a modality-agnostic arsenal of genetic medicines, Nvelop’s platforms are uniquely positioned to expand the reach of precision medicines to many previously undruggable diseases.
